a2f,, natural killer (NK) activity was not effected. The levels of soluble interleukin 2 receptor (sIL-2R) were similar in all patients and IL-2 was not detected in any patient. At the time of writing, of the total of 69 patients, seven have relapsed, of whom three were receiving IFN-a2fl, however there was no correlation between the absolute numbers of any lymphocyte subset with imminent relapse. The data suggest that the recovery of a specific lymphocyte subset(s) in peripheral blood is unlikely to be associated with the maintenance of response after intensive therapy.
Multiple myeloma (MM) is a disease of the B-cell lineage and remains incurable. Encouraging results from two clinical studies suggest that maintenance therapy with interferon a2, (IFN-a2fp) after intensive therapy with autologous bone marrow rescue (ABMR) (Attal et al., 1992; Cunningham et al., 1993) increases the duration of response and may prolong survival (Cunningham et al., 1993) . Since this therapeutic benefit is confined to patients who have had a complete response to treatment, it has been suggested that is only effective in patients who have had a substantial reduction of the tumour burden (Attal et al., 1992) . Thus far, there has been no indication that IFN-X2,0 improves the clinical status after intensive therapy, suggesting that the mechanism(s) involved in its therapeutic efficacy is concerned with the maintenance of tumour homeostasis rather than direct cytotoxicity.
The existence of monoclonal gammopathies of undetermined significance (MGUS) and plateau phase MM shows that monoclonal B cells can be kept under homeostatic control in vivo. In the case of plateau phase disease, this has been attributed to complex interactions between the malignant clone and the immune system (Joshua, 1988) . Several lines of evidence suggest that the evolution of the disease is influenced by the behaviour of immunoregulatory cells. Idiotype-reactive T cells have been found in MM patients with early stage disease (Dianzani et al., 1988; Osterborg et al., 1991) and high levels of interluekin 2 (IL-2) have been correlated with prolonged survival (Cimino et al., 1990) . In contrast, high levels of soluble IL 2 receptor (sIL-2R) in peripheral blood correlated with active disease (Vacca et al., 1991) and low CD4+ cell numbers have been associated with both advanced clinical disease and shorter survival (San Miguel et al., 1992) .
Massaia et al. (1993) have shown that activation of CD3+ lymphocytes from MM patients in vitro results in greater production of IFN-y than that produced from normal donor cells. This may have an association with putative tumour control in vivo since IFN-y, as well as IL-2, induces the differentiation of allergen-specific T cells in vitro to TH-1 clones and is induced by IFN-oa (Parronchi et al., 1992) .
As well as T cell-mediated immunoregulation, there is evidence that natural killer (NK) and lymphocyte-activated killer (LAK) cells may play a role in the regulation of MM. Although the number of precursors of cytotoxic cells may be reduced in patients with MM and LAK activity of peripheral blood T-and non-T lymphocytes is reduced compared with normal donors (Massaia et al., 1989) , both cellular and humoral effector mechanisms are retained that can regulate the behaviour of MM cells in model systems (Abbas, 1979; Rohrer and Lynch, 1979) . Despite a reduction in NK activity in patients with advanced MM (Osterborg et al., 1990) a signifigant increase has been found in patients with early stage disease (Gonzalez et al., 1992) and in patients following response to treatment or during plateau phase (Osterborg et al., 1990) . In vitro exposure of peripheral blood mononuclear cells from MM patients to IFN-a2fl increases NK activity (Uchida et al., 1984) and in vivo administration of IFN-a2p increased NK activity in patients given the cytokine as sole treatment (Einhorn et al., 1982) .
The aim of this study was to determine whether the recovery of one or more lymphocyte subsets associated with immune regulation is enhanced in patients receiving highdose melphalan (HDM) in combination with ABMR or peripheral blood stem cell rescue (PBSCR) 
Results

Lymphocyte analysis
The clinical status of MM patients used in this study at the time of examining the lymphocyte subsets is shown in Table  I . Although total white cell counts (WBCs) remained significantly lower in patients who received IFN-X2,i for prolonged periods after intensive therapy than in patients who had no further treatment (P<0.02) or normal volunteers (P<0.0002), this was not a reflection of a general inhibition of recovery among each of the lymphocyte subsets (Table II) . Despite a significant reduction in B-cell numbers in all patients after HDM, IFN-a2 had no effect on their recovery compared with that seen among patients who had no further treatment, and numbers returned to levels similar to those in normal volunteers 12 months after HDM. In contrast, IFNa2p inhibited the recovery of CD3+, CD4+/CD3+, CD8+/ CD3 +, CD16+/CD3-and CD56+/CD3 -lymphocytes. Since HDM also inhibited the recovery of CD4+/CD3+ T cells, the poor recovery in this subset was augmented by IFN-a2f. The data are summarised in Table II. NK activity NK activity correlated with absolute numbers of CD16+/ CD3-lymphocytes (r= 0.616) (Figure 1 ) but not with CD56+/CD3-cells (data not shown). Although absolute numbers of both CD16+/CD3-and CD56+/CD3-lymphocytes remained low in patients receiving long-term treatment with IFN-a2,i (Table II) , there was no significant difference between NK activity in patients or normal volunteers. The mean lytic activity was 60% + 6.2% in normal volunteers, 57.8% + 4.2% in patients who had no further treatment and 51.75% + 6.0% in patients on IFN-CX2fi (Figure 2 ).
sIL-2R and IL-2
Analysis of sIL-2R in serum from the patients who were taking IFN-a2 compared with those who were not showed that there was no significant difference between the levels compared with that reported for normal volunteers. The Although IFN-z2 has been used as maintenance therapy after HDM for more than 6 years at the Royal Marsden Hospital, the mechanism by which it regulates the proliferation of MM remains elusive. Examination of peripheral blood samples after short (median time, 3 months) and long (>12 months) exposure to IFN-i2 failed to identify the enhanced recovery of a specific lymphocyte subset(s) which might be a prognostic indicator for the anti-proliferative effect of Several authors have reported that continuous treatment with IFN-z2 suppresses the peripheral blood WBC but that recovery is rapid following cessation of treatment (Klingemann et al., 1991) . Reduced numbers of most lymphocyte subsets contributed significantly to the delayed recovery of the WBC in patients receiving IFN-i22 in addition to a longtime inhibitory effect on the recovery of CD4-cell caused by therapy (Bergmann et al., 1984) . However, despite the reduction in B cell numbers in all patients during the first 12 months after intensive therapy, their subsequent recovery was not inhibited by IFN-o2 and cell numbers were similar to those in normal volunteers at longer time intervals. Previous studies have considered the role of immunoregulatory cells as prognostic indicators in untreated patients with MM (Massaia et al., , 1989 and the effects of IFNz2 on these cells in vitro (Uchida et al., 1984) or as a single agent in vivo (Einhorn et al., 1982) . The association of low numbers of CD4+ lymphocytes with poor prognosis (Bergmann et al., 1984) is clearly inappropriate as a criterion of imminent relapse after intensive therapy, since their recovery is known to be inhibited by chemotherapy (Bergmann et al., 1984) . In our patients, the delayed recovery of CD4+ lymphocytes was increased by IFN-2 whereas the number of CD8+ cells was similar to those of normal volunteers in patients who had no further treatment within 12 months after intensive therapy. These data suggest that despite the differential sensitivity of CD4+ and CD8+ lymphocytes to chemotherapy they are equally sensitive to the anti-proliferative effects of IFN-2.
Although increased numbers of activated NK cells have been found in the peripheral blood of untreated patients with early stage disease (Osterborg et al., 1990; Gonzalez et al., 1992) , there was no indication that the magnitude of the IFN--2rinduced enhancement of NK activity correlated with clinical response to IFN-x2p (Einhorn et al., 1982 Given that MM is a disease of the B-cell lineage, the recovery of B-cells in patients receiving IFN-xX raises questions concerning both the putative stem cell in MM as well as the mechanism by which tumour homeostasis is achieved. Montes Borinaga (1993) showed that MM cells can be cultured in vitro from patients receiving IFN-z2 as maintenance therapy during remission after HDM/ABMR suggesting that the effect of the cytokine in vivo is likely to be cytostatic rather than cytocydal. Although the stem cell in MM has not been identified several authors agree that it is likely to arise after class-switching immediately before or at the level of the memory B-cell (Ralph et al., 1993; Sahota et al., 1994) . The failure of neutralising antibody to IFN-:, to persist in patients receiving the cytokine as maintenance therapy led to the suggestion that memory B-cells may not be involved (Millar and Bell, 1995) . An alternative conclusion could be that the proliferation and maturation of memory cells may be inhibited in patients receiving the cytokine. Despite our failure to identify a particular lymphocyte subset in the peripheral blood that may effect tumour homeostasis, we cannot exclude the possibility that changes may have occurred in the milieu of the bone marrow or lymph nodes that might account for inhibition of tumour cell proliferation. Although sequestration of cytotoxic T cells and/or NK cells to those sites may be responsible for localised control, the relapse of three patients while receiving IFN-22 within 6 months of HDM with PBSCR suggets that the efficacy of such a control mechanism would require a fine balance between the residual tumour burden and the anti-tumour effect of the cytokine.
The lack of correlation between absolute numbers of lymphocyte subsets with relapse may be indicative of an alternative mechanism dependent on changes in the cytokine profile at specific sites within the bone marrow or lymph nodes. There is increasing evidence that the cytokine profile of the natural immune response probably determines the phenotype of the specific immune response (Romagini, 1992) . For example, Thl (which produce IL-2 and IFN-y) and Th2 (which produce IL-4 and IL-5) lymphocytes are associated with markedly different functions whereas ThO cells show an unrestricted lymphokine pattern (Firestein et al., 1989) .
Although IFN-a,2 promotes the differentiation of allergenspecific T cells into Thl instead of Th2 clones (Parronchi et al., 1992) , IL-2 was not detected in the serum from any patient, neither were the levels of sIL-2R different from those in patients who did not receive the cytokine. However, the net effect of INF-z2 in vivo may result in the localised release of INF-y and IL-2 by different T cell subsets depending on their proximity to cells that can respond and may be insufficient to be detected in serum.
In conclusion, there was no enhanced recovery of a particular lymphocyte subset(s) in peripheral blood samples that may account for the anti-tumour effect of IFN-22 as maintenance therapy. It seems likely that the anti-proliferative effect of the cytokine is determined by events that occur at localised sites within the bone marrow or lymph nodes and that such events are dependent critically on the residual tumour mass.
